Generic Olumiant Availability

Last updated on Jun 11, 2025.

Olumiant is a brand name of baricitinib, approved by the FDA in the following formulation(s):

OLUMIANT (baricitinib - tablet;oral)

• Manufacturer: ELI LILLY AND CO
  Approval date: May 31, 2018
  Strength(s): 2MG ^{[RLD] [AB]}
• Manufacturer: ELI LILLY AND CO
  Approval date: October 8, 2019
  Strength(s): 1MG ^{[RLD] [AB]}
• Manufacturer: ELI LILLY AND CO
  Approval date: May 10, 2022
  Strength(s): 4MG ^{[RLD] [AB]}

Is there a generic version of Olumiant available?

No. There is currently no therapeutically equivalent version of Olumiant available in the United States.

Note: Fraudulent online pharmacies may attempt to sell an illegal generic version of Olumiant. These medications may be counterfeit and potentially unsafe. If you purchase medications online, be sure you are buying from a reputable and valid online pharmacy. Ask your health care provider for advice if you are unsure about the online purchase of any medication.

See also: Generic Drug FAQ.

Related patents

Patents are granted by the U.S. Patent and Trademark Office at any time during a drug's development and may include a wide range of claims.

• Antiviral JAK inhibitors useful in treating or preventing coronaviridae infections
  Patent 11,045,474
  Issued: June 29, 2021
  Inventor(s): Gavegnano; Christina et al.
  Assignee(s): Emory University (Atlanta, GA); The United States Government as Repersentative by the Department of Veterans Affairs (Washington, DC)
  

  Compounds, compositions, and methods of treatment and prevention of HIV infection are disclosed. The compounds are pyrrolo[2,3-b]pyridines and pyrrolo[2,3-b]pyrimidine JAK inhibitors. Combinations of these JAK inhibitors and additional antiretroviral compounds, such as NRTI, NNRTI, integrase inhibitors, entry inhibitors, protease inhibitors, and the like, are also disclosed. In one embodiment, the combinations include a combination of adenine, cytosine, thymidine, and guanine nucleoside antiviral agents, optionally in further combination with at least one additional antiviral agent that works via a different mechanism than a nucleoside analog. This combination has the potential to eliminate the presence of HIV in an infected patient.

  Patent expiration dates:

  • November 30, 2032
    
    ✓ 
    Patent use: TREATMENT OF CORONAVIRUS DISEASE 2019 (COVID-19) IN HOSPITALIZED ADULTS REQUIRING SUPPLEMENTAL OXYGEN, NON-INVASIVE OR INVASIVE MECHANICAL VENTILATION, OR EXTRACORPOREAL MEMBRANE OXYGENATION (ECMO)
• Methods for treating hair loss disorders
  Patent 11,806,555
  Issued: November 7, 2023
  Inventor(s): Christiano; Angela M. et al.
  Assignee(s): The Trustees of Columbia University in the City of New York (New York, NY)
  

  The invention provides for methods for treating a hair loss disorder in a subject by administering a Janus Kinase/Signal Transducers and Activators of Transcription inhibitor.

  Patent expiration dates:

  • November 2, 2031
    
    ✓ 
    Patent use: TREATMENT OF ADULT PATIENTS WITH SEVERE ALOPECIA AREATA
• Azetidine and cyclobutane derivatives as JAK inhibitors
  Patent 8,158,616
  Issued: April 17, 2012
  Inventor(s): Rodgers James D. & Shepard Stacey
  Assignee(s): Incyte Corporation
  

  The present invention relates to azetidine and cyclobutane derivatives, as well as their compositions, methods of use, and processes for preparation, which are JAK inhibitors useful in the treatment of JAK-associated diseases including, for example, inflammatory and autoimmune disorders, as well as cancer.

  Patent expiration dates:

  • May 31, 2032
    
    ✓ 
    Drug substance
    ✓ 
    Drug product
• Azetidine and cyclobutane derivatives as JAK inhibitors
  Patent 8,420,629
  Issued: April 16, 2013
  Inventor(s): Rodgers James D. & Shepard Stacey
  Assignee(s): Incyte Corporation
  

  The present invention relates to azetidine and cyclobutane derivatives, as well as their compositions, methods of use, and processes for preparation, which are JAK inhibitors useful in the treatment of JAK-associated diseases including, for example, inflammatory and autoimmune disorders, as well as cancer.

  Patent expiration dates:

  • March 10, 2029
    
    ✓ 
    Patent use: TREATMENT OF RHEUMATOID ARTHRITIS
• Antiviral JAK inhibitors useful in treating or preventing retroviral and other viral infections
  Patent 9,089,574
  Issued: July 28, 2015
  Inventor(s): Gavegnano Christina & Schinazi Raymond F.
  Assignee(s): EMORY UNIVERSITY
  

  Compounds, compositions, and methods of treatment and prevention of HIV infection are disclosed. The compounds are pyrrolo[2,3-b]pyridines and pyrrolo[2,3-b]pyrimidine JAK inhibitors. Combinations of these JAK inhibitors and additional antiretroviral compounds, such as NRTI, NNRTI, integrase inhibitors, entry inhibitors, protease inhibitors, and the like, are also disclosed. In one embodiment, the combinations include a combination of adenine, cytosine, thymidine, and guanine nucleoside antiviral agents, optionally in further combination with at least one additional antiviral agent that works via a different mechanism than a nucleoside analog. This combination has the potential to eliminate the presence of HIV in an infected patient.

  Patent expiration dates:

  • November 30, 2032
    
    ✓ 
    Patent use: TREATMENT OF CORONAVIRUS DISEASE 2019 (COVID-19) IN HOSPITALIZED ADULTS REQUIRING SUPPLEMENTAL OXYGEN, NON-INVASIVE OR INVASIVE MECHANICAL VENTILATION, OR EXTRACORPOREAL MEMBRANE OXYGENATION (ECMO)
• Methods for treating hair loss disorders
  Patent 9,737,469
  Issued: August 22, 2017
  Inventor(s): Christiano Angela M. & Clynes Raphael
  Assignee(s): The Trustees of Columbia University in the City of New York
  

  The invention provides for methods for treating a hair loss disorder in a subject by administering a Janus Kinase/Signal Transducers and Activators of Transcription inhibitor.

  Patent expiration dates:

  • November 2, 2031
    
    ✓ 
    Patent use: TREATMENT OF ADULT PATIENTS WITH SEVERE ALOPECIA AREATA

Related exclusivities

Exclusivity is exclusive marketing rights granted by the FDA upon approval of a drug and can run concurrently with a patent or not. Exclusivity is a statutory provision and is granted to an NDA applicant if statutory requirements are met.

• Exclusivity expiration dates:

  • May 10, 2025 - TREATMENT OF COVID-19 IN HOSPITALIZED ADULTS REQUIRING SUPPLEMENTAL OXYGEN, NONINVASIVE OR INVASIVE MECHANICAL VENTILATION, OR EXTRACORPOREAL MEMBRANE OXYGENATION (ECMO)
  • June 13, 2025 - TREATMENT OF ADULT PATIENTS WITH SEVERE ALOPECIA AREATA

Related/similar drugs

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.

Medical Disclaimer